Serum Gamma Glutamyltransferase (GGT) in Coronary Artery Disease: Exploring the Asian Indian Connection

Kunal K. Singh, Aditya Kapoor, Roopali Khanna, Ankit Sahu, Vishwas Kapoor1, Sudeep Kumar, Naveen Garg, Satyendra Tewari, Pravin Goel

Departments of Cardiology and 1Biostatistics and Health Informatics, Sanjay Gandhi PGIMS, Lucknow, Uttar Pradesh, India

ABSTRACT

Background: There is a need to identify novel markers for CAD, independent of traditional CV risk factors. One of these is gamma-glutamyl transferase (GGT), a marker of increased oxidative stress. Given the high prevalence of CAD in Asian Indians, the link of GGT and CAD in them needs to be studied.

Aim: To assess GGT in patients with angiographically documented CAD.

Methods and Results: Two hundred patients aged 58.1 ± 9.95 years, 73% males, hypertension 56%, diabetes 40% were included. Mean GGT was 63.6 ± 44.33 (10–269 U/L). The levels of GGT progressively increased in those with single/double or triple-vessel CAD (36.5, 61.5, and 87 U/L, respectively, P < 0.001). Using objective criteria of CAD burden (SYNTAX and Gensini scores), we reaffirmed these findings. GGT in patients with SYNTAX tertiles 0–22, 23–32, and >33 was 33, 62, and 97 U/L, respectively and in Gensini tertiles 0–17.65, 17.66–56.65, >56.66 was 32, 52, and 88 U/L, respectively, all P < 0.001. SYNTAX score ≥ 23 was present in only 23% patients in GGT tertile 1 (<41 U/L), whereas 60% and 94% in GGT tertiles 2 and 3 had SYNTAX ≥ 23. Significant positive correlation was seen between GGT and SYNTAX (r = 0.634) and Gensini score (r = 0.772).

Conclusions: In this study, GGT had an independent correlation with angiographic severity of CAD and SYNTAX and Gensini scores. Although the existing evidence seems biologically plausible, more studies are needed to explore the potential role of this inexpensive marker for predicting disease burden in patients with CAD.

Keywords: Coronary artery disease, Gamma-glutamyltransferase (GGT), Gensini score, Indians, SYNTAX

INTRODUCTION

Coronary artery disease (CAD) is the major cause of morbidity and mortality worldwide. Although conventional cardiovascular (CV) risk factors such as hypertension (HT), diabetes mellitus (DM), dyslipidemia, and smoking have a strong association with development of CAD, many patients have CAD even without the presence of such risk factors. Asian Indians not only have a higher prevalence of CAD as compared to Western counterparts, but the onset is often at a younger age, and the severity of CAD is also much more, highlighting the need to explore additional biomarkers to explain this higher risk and improve risk stratification. Despite extensive efforts for the identification of biomarkers for early assessment of CAD, only a limited number of useful biomarkers have been identified, and there is a need to identify and validate novel markers.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKLHRPMedknow_reprints@wolterskluwer.com

How to cite this article: Singh KK, Kapoor A, Khanna R, Sahu A, Kapoor V, Kumar S, et al. Serum Gamma Glutamyltransferase (GGT) in coronary artery disease: Exploring the Asian Indian connection. Ann Card Anaesth 2022;25:408-13.
Gamma glutamyl transferase (GGT) is an enzyme which is responsible for the extracellular catabolism of glutathione and acts as an important antioxidant in mammalian cells.

Whereas increased serum GGT levels are known in patients with hepatobiliary dysfunction, population-based studies have also identified a predictive value of serum GGT for both CV and all-cause mortality.

Imbalance between oxidant/antioxidant system as well as inflammation have been proposed as the major mechanisms for the association of GGT with pathogenesis of CAD. The presence of catalytically active GGT molecules in human atheromatous plaque and GGT-triggered iron-catalyzed low-density lipoprotein (LDL) oxidation, as well as production of reactive oxygen species are also responsible for this association. These events play a central role in the evolution of atherosclerosis including formation of the fibrous cap, cellular apoptosis, plaque erosion and rupture, and enhanced platelet aggregation and thrombosis.

Evidence from various epidemiological studies suggests that higher serum GGT levels are associated with higher incidence of CVD and an increased risk of abnormal vascular stiffness, coronary flow reserve impairment, DM, metabolic syndrome, myocardial infarction, stroke, cardiac, and all cause death.

Data from the third US National Health and Nutrition Examination Survey, 1988–1994 (NHANES III), involving 14,950 adult NHANES participants, revealed that elevated GGT was associated with all-cause mortality [hazard ratio (HR) 1.6] in the age adjusted model, deaths due to diabetes (HR 4.9), death from CVD and cancer (HR 1.5). These HRs were consistent with those reported from an Austrian database as well. An age and gender related gradient of GGT with CV events has also been reported; amongst 28,838 Finnish men and women, GGT-related HRs were higher among individuals under age 60, both for nonfatal heart attack and fatal coronary heart disease (CHD).

Other studies have also reported a dose-response relationship between GGT and CV mortality with higher levels of serum GGT being associated with a 20%, 54%, and 34% increased risk of coronary heart disease (CHD), stroke, and both stroke and CHD, respectively.

Typically identified as a marker of hepatobiliary dysfunction, GGT appears to be a promising biomarker of oxidative stress and cardiovascular risk. Its association with CAD needs to be explored further, especially in Indian patients, given the exponentially rising trends of CAD in these patients. It is not only important to correlate if serum levels of GGT are elevated in patients with CAD, but it is also pertinent to assess if its levels correlate with the disease burden in patients with CAD, as quantified by single vs multi-vessel disease and established angiographic scores.

Aim
The aim of current study was to investigate the association of GGT with CAD in Indian patients with signs or symptoms of CAD (rest angina/angina on effort/ECG changes) who were scheduled to undergo coronary revascularization.

METHODS
The study was a prospective, single-center study that enrolled 200 patients from January 2019 to December 2020 after an informed written consent, and the study conformed to institutional ethical guidelines. Patients were excluded if they had active liver disease, acute renal failure or chronic kidney disease, cancer, concomitant inflammatory conditions, active infection, or active alcohol consumption.

Detailed history and examination were performed for all enrolled patients, and blood samples were collected before intervention. A 12 lead ECG and trans-thoracic echocardiography were performed in all patients. GGT, HbA1c, renal function tests, and liver function tests were performed on Spectra make, Pro M model Clinical Chemistry Analyzer. Hypertension and diabetes mellitus were defined as per routine standard criteria.

The overall severity of coronary stenosis, complexity, and coronary atherosclerotic burden was quantified by Gensini and the SYNTAX score. The Gensini score was calculated as total of the sum of severity score assigned based on the degree of angiographic luminal stenosis on visual assessment in each segment of the coronary artery. The final GS is the sum of all the lesion scores.

The SYNTAX score was calculated based on coronary artery lesion with diameter stenosis greater than 50%, arterial dominance, coronary segment involved, presence of total occlusion, bifurcation or trifurcation or not, aorto-ostial lesion, lesion length, calcification, tortuosity, and thrombus. The final calculation was based on the online SYNTAX calculator (version 2.28).

Statistical analysis- The appropriate statistical tests were used to analyze the data recorded, like GGT, SYNTAX, and GENINSI score. Numerical variables were reported as
the mean ± SD or median (IQR), and categorical variables were represented as frequency (%). Normality of data was tested using Shapiro–Wilk test or Kolmogrov–Smirnov test. For homogeneously distributed data, independent *t*-test and one way ANOVA was used, whereas Mann–Whitney U test and Kruskal–Wallis test was used for skewed data. Chi-square test were used to compare categorical variables between two groups. Correlation among variables was studied using Pearson’s correlation coefficient. All test of statistical significance were considered significant at 0.05 levels.

**RESULTS**

A total of 200 patients were recruited from January 2019 to December 2020. The mean age of the study population was 58.1 ± 9.95 years (range 34–84 years) and of these, 73.7% were males. Hypertension was present in 56% of patients, DM was noted in 40%, and tobacco consumption was present in 23%. The most common presentation was chronic stable angina (CSA), which was seen in 64.7% patients followed by ST-segment elevation myocardial infarction (STEMI) which was seen in 23.7%, and non-STEMI (NSTEMI) was seen in 11.6% of patients. The other biochemical and demographic parameters are listed in Table 1. GGT values ranged from 10 to 269 U/L (mean 63.6 U/L) in the study population. On angiography, most common finding was single-vessel disease (SVD 40%, n = 81) followed by double-vessel disease (DVD 34.7%, n = 69), and 25.3% (n = 50) patients had triple-vessel disease (TVD).

**Relation of GGT with angiographic severity of CAD based on SVD/DVD/TVD:** We found a significant positive association between serum GGT and patients with angiographically documented CAD. The median level of serum GGT among patients with SVD, DVD, and TVD was 36.5 u/L, 61.5 u/L, and 87 u/L, respectively. [Table 2 and Figure 1].

**Relation of GGT with angiographic severity of CAD based on angiographic scores:** The median level of serum GGT among patients with SYNTAX score (0–22), (23–32), and (≥33) was 33 u/L, 62 u/L, and 97 u/L, respectively. [Table 2/ Figure 2]. Amongst patients with Gensini score (0–17.65), (17.66–56.65), and (≥56.66), the median GGT level was 32 u/L, 52 u/L, and 88 u/L, respectively. [Table 2 and Figure 3].

Logistic regression analysis showed a significant association of GGT with increasing severity of CAD as shown in Table 3. Furthermore, a significant positive correlation was also noted between serum level of GGT and Gensini score (r = 0.772, *P* < 0.001) and SYNTAX score (r = 0.634, *P* < 0.001). Figure 4.

Stratifying the patient population based on GGT tertiles <41 U/L, 41–71 U/L, and >71 U/L. [Table 4]
revealed that SYNTAX scores was incrementally more severe in those with in the higher GGT teriles (15.2 ± 8.12, 21.2 ± 7.72, and 32 ± 6.22, \( P < 0.001 \)). In the GGT tertile 1, 78% had SYNTAX score ≤22, and 18.4% and 4.6%, respectively had SYNTAX 23–32 and ≥33. The corresponding % for GGT tertile 2 and 3 were respectively 39.8%, 54.4%, and 5.8% and 5.9%, 26.9%, and 67.2%, all \( P < 0.001 \).

Similarly, Gensini scores increased across the strata of the GGT tertiles (20.1 ± 18.37, 31.3 ± 18.92, and 83.3 ± 30.07, \( P < 0.001 \)). A Gensini score of 17.6–56.65 and ≥56.66 was noted in 66.1%, 24.6%, and 9.3% in GGT tertile 1, for GGT tertile 2, the % values were 27.9%, 63.3%, and 8.8%, whereas for GGT tertile 3, the corresponding % values were 5.9%, 13.4%, and 80.5%, all \( P < 0.001 \).

Correlation with other parameters: GGT showed a significant correlation with CRP (\( r = 0.360, P_\text{corr} = 0.001 \)) and with systolic BP (\( r = 0.148, P = 0.042 \)), but no significant correlation was observed with other biochemical parameters or conventional CV risk factors like DM, dyslipidemia, and tobacco consumption.

**DISCUSSION**

In the current study, amongst 200 patients (mean age 58.1 years) who underwent coronary angiography before scheduled revascularization (2/3rd for chronic stable angina), the mean GGT level was 63.6 ± 44.33 U/L. Mean GGT level were slightly higher than what was previously reported in studies by Ghatge et al.[24] (30.94 ± 0.90 U/L), Bijapur et al.[25] (39.48 ± 22.91 U/L), Emdin et al.[26] (39·0 ± 39·2 U/L), and Aksakal et al.[27] (36.7 ± 17.3 U/L), although in
the analysis by Arasteh et al.\cite{28} almost similar levels were reported (mean GGT 70.66 U/L).

Serum GGT levels were significantly higher in patients with double/triple vessel CAD as compared to those with single-vessel disease, highlighting the association of GGT with increasing severity of obstructive CAD. Interestingly, the median GGT levels in patients with SVD, DVD, and TVD in our study (36.5 u/L, 61.5 u/L, and 87 u/L, respectively) are almost similar to what was reported by Arasteh et al.\cite{28} (viz 55.6 ± 9.7, 71.7 ± 12.7, and 84.7 ± 13.4 U/L), who also noted that GGT levels progressively increased in patients with multi-vessel CAD.

We also analyzed the relationship of GGT levels with angiographic scores like SYNTAX for coronary lesion complexity and Gensini for coronary artery atherosclerotic burden. The level of serum GGT increased significantly with increasing SYNTAX scores in our study (33 u/L, 62 u/L, and 97 u/L, respectively in the tertiles of Synatx <22, 23–32, and ≥ 33). Similar findings were observed by Aksakal et al.,\cite{27} who in a Turkish study cohort, demonstrated an increase in GGT levels from low SYNTAX tertile to high tertile (32.2 ± 16.4, 38.5 ± 18.5, and 42.7 ± 15.9), in patients with stable angina pectoris.

We further attempted to establish the potential link between GGT and coronary artery atherosclerotic burden quantified by Gensini score analysis. Progressively higher GGT levels were seen in patients with higher Gensini scores (32 u/L, 52 u/L, and 88 u/L, respectively in the Gensini tertiles) To the best of our knowledge, none of the previous studies have correlated GGT levels with both measures of angiographic severity (SYNTAX for coronary lesion complexity) and Gensini (for coronary artery atherosclerotic burden).

The association between GGT and coronary lesion complexity (SYNTAX score) was further exemplified as shown in Table 4. SYNTAX score ≥ 23 was present in only 23% patients in GGT tertile 1 (<41 U/L), whereas 60% and 94% in GGT tertiles 2 and 3 had SYNTAX ≥ 23. Similarly, GGT was linearly associated with coronary artery atherosclerotic burden (Gensini score). Score ≥17.66 was noted in only 34% in GGT tertile 1, as compared to 72% and 94% in GGT tertiles 2 and 3, respectively.

A significant positive correlation between serum level of GGT and SYNTAX score (coronary lesion complexity) and Gensini score (coronary artery atherosclerotic burden) was noted. The correlation was slightly more robust with Gensini score (r = 0.772) compared to SYNTAX score (r = 0.634), although this was not statistically significant. This difference is most likely due to method of calculation of the scores as SYNTAX takes into account only lesions with > 50% stenosis, whereas Gensini score is more closely related to overall atherosclerotic burden and takes into account any degree of stenosis.

Few studies have found a correlation of GGT with other cardiovascular risk factors, such as hypertension, stroke, diabetes, dyslipidemia, and metabolic syndrome, and others have observed its association with inflammatory markers.\cite{24,29} We observed a correlation of GGT with CRP levels (r = 0.148, P = 0.042) and systolic BP (r = 0.148, P = 0.042), but not with presence of other CV risk factors such as DM, lipid levels, or smoking.

Gamma-glutamyl transferase (GGT), an enzyme that regulates intracellular glutathione and is a marker of increased oxidative stress has been linked to the pathogenesis of CAD by way of oxidant/antioxidant imbalance and inflammation.\cite{28} Our study adds to the growing evidence that higher levels of GGT may be associated both with coronary lesion complexity and coronary artery atherosclerotic burden, findings that need to be validated in future studies.

**Limitations**

Absence of a control arm, a small sample size from a single center, and lack of any outcome data represent important limitations. Due to the COVID pandemic, availability of controls and suboptimal follow up after discharge were important factors in this regard. We also did not measure any other biochemical markers of oxidative stress (due to cost logistics), which could have further added to the strengths of the study. Further studies should also perhaps focus on whether a single point assessment or serial assays are likely to have any clinical implications.

**CONCLUSION**

The present study demonstrated the value of serum level of GGT as a biomarker for predicting severity of CAD amongst patients with documented CAD on coronary angiography. To the best of our knowledge, this is the first study evaluating relationship of serum level of GGT with coronary lesion complexity (SYNTAX score) and coronary artery atherosclerotic burden (Gensini score) in an Indian population. Higher GGT levels potentially denote increased oxidative stress and are hence may be mechanistically linked to development of CAD. As GGT is a low cost and readily available assay, validating these data in a larger cohort and translating the findings into clinical practice would be clinically pertinent.
Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J 2010;74:213–20.
2. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AB, Garside DB, et al. Major risk factors as antecedents of fatal and nonfatal coronary artery disease events. JAMA 2003;290:8917.
3. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:8988904.
4. Goyal A, Yusuf S. The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res 2006;124:23544.
5. Sharma M, Ganguly NK. Premature coronary artery disease in Indians and its associated risk factors. Vasc Health Risk Manag 2005;1:21725.
6. Meister A. Metabolism and transport of glutathione and other-glutamyl compounds. In: Larsson A, Orrenius S, Holmgren A, Mannervik B, editors. Functions of Glutathione: Biochemical, Toxicological and Clinical Aspects. New York: Raven Press; 1983. p. 1–22.
7. Brenner H, Rothenbacher D, Arndt V, Schuberth S, Fraisse E, Fliedner TM. Distribution, determinants, and prognostic value of gammaglutamyltransferase-dependent iron reduction and γ-glutamyltransferase-dependent H2O2 production and S-thiolation. Free Radic Biol Med 2001;38:263–355.
8. Mao Y, Qi X, Xu W, Song H, Xu M, Ma W, et al. Serum gamma-glutamyltransferase: A novel biomarker for coronary artery disease. Med Sci Monit 2014;20:706–10.
9. Koenig G, Seneff S. Gamma-glutamyltransferase: A predictive biomarker of cellular antioxidant inadequacy and disease risk. Dis Markers 2015;2015:818570.
10. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and γ-glutamyltransferase and mortality in the United States population. Gastroenterology 2009;136:477–85.
11. Kazemi-Shirazi L, Endler G, Winkler S, Schickbauer T, Wagner O, Marsik C. Gamma glutamyltransferase and longterm survival: Is it just the liver? Clin Chem 2007;53:940-6.
12. Lee DH, Silventoinen K, Hu G, Jacobs DR Jr, Jousilahti P, Sundvall J, et al. Serum gammaglutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28 838 middle-aged men and women. Eur Heart J 2006;27:2170-6.
13. Ruttmann E, Brant IJ, Conein H, Diem G, Rapp K, Ulmer H, et al. γ-Glutamyltransferase as a risk factor for cardiovascular disease mortality: An epidemiological investigation in a cohort of 163 944 Austrian adults. Circulation 2005;112:2130–7.
14. Lee W, Ryoo JH, Suh BS, Lee J, Kim J. Association of coronary artery calcification and serum gamma-glutamyltransferase in Korean. Atherosclerosis 2013;226:269-74.
15. Rampidis GP, Benetos G, Benz DG, Giannopoulos AA, Buechel RR. A guide for Gensini Score calculation. Atherosclerosis 2019;287:181-3.
16. Peterson B, Trell E, Kristensson H, Fex G, Yettra M, Hood B. Inflammation as a potential mechanism in atherosclerosis. J Cardiovasc Med Surg 2020;6:29-32.
17. Kazemi-Shirazi L, Endler G, Winkler S, Schickbauer T, Wagner O, Marsik C. Gamma glutamyltransferase and longterm survival: Is it just the liver? Clin Chem 2007;53:940-6.
18. Lee DH, Silventoinen K, Hu G, Jacobs DR Jr, Jousilahti P, Sundvall J, et al. Serum gammaglutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28 838 middle-aged men and women. Eur Heart J 2006;27:2170-6.
19. Ruttmann E, Brant IJ, Conein H, Diem G, Rapp K, Ulmer H, et al. γ-Glutamyltransferase as a risk factor for cardiovascular disease mortality: An epidemiological investigation in a cohort of 163 944 Austrian adults. Circulation 2005;112:2130–7.
20. Abar AI, Yilmaz OC, Akin K, Selcoki Y, Er O, Eryomacu B. Association between gamma-glutamyltransferase and coronary artery calcification. Int J Cardiol 2013;167:1264-7.
21. Lee W, Ryoo JH, Suh BS, Lee J, Kim J. Association of coronary artery calcification and serum gamma-glutamyltransferase in Korean. Atherosclerosis 2013;226:269-74.
22. Rampidis GP, Benetos G, Benz DG, Giannopoulos AA, Buechel RR. A guide for Gensini Score calculation. Atherosclerosis 2019;287:181-3.
23. Ong AT, Serruya PW, Mohr FW, Morice MC, Kappetein AP, Holmes DR Jr, et al. The SYNERGY between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: Design, rationale, and run-in phase. Am Heart J 2006;151:1194-204.
24. Ghatge M, Sharma A, Vangala RK. Association of γ-glutamyltransferase with premature coronary artery disease. Biomed Rep 2016;4:307–12.
25. Bijapur SJ, BS A, Nanjappa MC, Reddy PT, Katheria R. Gamma-Glutamyl Transferase: A Novel Biomarker for Predicting Coronary Artery Disease. J Cardiovasc Med Surg 2020;6:29-32.
26. Emdin M, Passino C, Michelassi C, Titta F, L'abatte A, Donato I, et al. Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction. Eur Heart J 2001;22:1802-7.
27. Aksakal E, Tanboga IH, Kurt M, Kaygın MA, Kaya A, Isik T, et al. The relation of serum gamma glutamyltransferase levels with coronary lesion complexity and long-term outcome in patients with stable coronary artery disease. Atherosclerosis 2012;221:596–601.
28. Araste S, Mouhebati M, Avan A, Esmaeili H, Ghazizadeh H, Mahdizadeh A, et al. Serum level of gamma-glutamyltransferase as a biomarker for predicting stenosis severity in patients with coronary artery disease. Indian Heart J 2018;70:788–92.
29. Poelzl G, Eberl C, Achrainer H, Doerler J, Pachinger O, Frick M, et al. Prevalence and prognostic significance of elevated gammaglutamyltransferase in chronic heart failure. Circ Heart Fail 2009;2:294–302.
30. Emdin M, Passino C, Michelassi C, Donato I, Pompella A, Paolicchi A. Additive prognostic value of gammaglutamyltransferase in coronary artery disease. Int J Cardiol 2009;136:805.